Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lidocaine and dibucaine

This article was originally published in The Tan Sheet

Executive Summary

NDMA asks Consumer Products Safety Commission to reconsider its proposal to require child-resistant packaging for lidocaine- and dibucaine-containing products in a July 6 letter. Based on 1987-1991 data from the American Association of Poison Control Centers, NDMA said there have been 2,683 reported ingestions of lidocaine by children under six years old and no deaths, and 535 dibucaine ingestions resulting in two deaths. NDMA estimated that "about 50 mil." packages of lidocaine- and dibucaine-containing OTC anesthetics were sold from 1987 to 1991. A briefing package on topical lidocaine/dibucaine child-safety caps is expected to be issued to CPSC commissioners for consideration in September ("The Tan Sheet" July 26, p. 12).
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel